Ovarian Cancer

More Results From Antibody Therapy Trial Published

Published in Cancer Weekly, August 21st, 2001

AltaRex Corp. (ALXFF) reported further results from its 55-patient OvaRex^R trial for ovarian cancer patients with biochemical relapse following primary surgery and chemotherapy.

The primary analysis for this Phase II, multicenter, double-blind, placebo-controlled trial was designed to compare time to disease relapse in patients who demonstrate an immune response to OvaRex monoclonal antibody (MAb) versus patients who do not. Importantly, results from the trial provide, for the first time, validated quality-of-life data associated with the administration of OvaRex MAb as compared with placebo.

The trial, with Dr. Michael Bookman of the Fox...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-08-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry